论文部分内容阅读
目的比较培美曲塞单药或联合天佛参口服液在老年晚期肺腺癌患者中的近期疗效及安全性。方法选择初治的老年晚期肺腺癌患者60例,随机分为试验组和对照组,试验组予培美曲塞500 mg/m2,第1天,同时给予天佛参口服液20 ml,3次/d,每21 d为1个周期,连用2周期;对照组单用培美曲塞化疗。评估所有患者的近期疗效,检测免疫指标的变化,记录化疗不良反应及体力状况评分,并进行组间比较。结果 2组患者的近期有效率分别为53.5%及46.7%,疾病控制率分别为66.7%、63.3%,差异无统计学意义(P>0.05);2组免疫指标均较治疗前有明显改善(P<0.05),但试验组改善程度更显著(P<0.05);试验组体力状况的改善明显优于对照组(P<0.05);2组Ⅲ~Ⅳ度不良反应差异无统计学意义(P>0.05)。结论老年晚期肺腺癌患者接受培美曲塞与天佛参的联合治疗,可提高免疫功能,改善体力状况。
Objective To compare the short-term efficacy and safety of pemetrexed alone or in combination with Tianfo Shen oral liquid in elderly patients with advanced lung adenocarcinoma. Methods Sixty patients with newly diagnosed advanced adenocarcinoma of the lung were selected and randomly divided into experimental group and control group. Pemetrexed 500 mg / m2 was given to the experimental group on the first day, 20 ml of Tianfo Shen oral liquid Times / d, every 21 d for a cycle, once every 2 cycles; control group pemetrexed alone chemotherapy. All patients were evaluated for short-term efficacy, changes in immune parameters, adverse reactions to chemotherapy, and physical status scores were recorded and compared between groups. Results The effective rates of the two groups were 53.5% and 46.7% respectively, and the disease control rates were 66.7% and 63.3% respectively, with no significant difference (P> 0.05). The immune indexes in both groups were significantly improved (P <0.05), but the improvement in the experimental group was more significant (P <0.05). The improvement of physical condition in the experimental group was significantly better than that in the control group (P <0.05). There was no significant difference in the adverse reactions of Ⅲ ~ > 0.05). Conclusions The combination therapy of pemetrexed and Tianfo ginseng in elderly patients with advanced lung adenocarcinoma can improve immune function and improve physical condition.